Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS3790a in Hematological Malignancies
NCT07220616Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Nov 2030
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
A Phase 2 trial of DS3790a in hematological malignancy, B-cell non-Hodgkin lymphoma, sponsored by Daiichi Sankyo Co., Ltd.. Started Jan 2026; status: recruiting.
02
Drugs
DS3790a
03
Conditions
hematological malignancyB-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07220616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220616.